Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Posts Strong Q3 Revenue Growth; R&D, Loss Trimmed

NEW YORK, Oct.16 (GenomeWeb News) - Illumina today posted a dramatic increase in third-quarter revenues atop fallen R&D expenditures and narrowed net loss.


Total revenue for the period ended Sept. 28 increased to $8.2 million from $3 million one year ago, the company said. Product sales, which increased to $6.5 million in the current third quarter from $1.3 million in the year-ago period, made up the brunt of total revenues. Receipts from services in the quarter remained relatively flat at around $1 million.


R&D spending in the quarter fell to $5.1 million from $6.4 million in the third quarter 2002. Consequently, net loss narrowed to $5.5 million, or $.17 per share, from $7.6 million, or $.24 per share, year over year, Illumina said.


The company said it had around $51.2 million in cash and investments as of Sept. 28.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.